Skip to main content
SpringerLink
Log in

Choosing Adjunctive Glaucoma Therapy

  • Chapter
  • First Online:
The Glaucoma Book

Abstract

Glaucoma is a group of optic neuropathies characterized by retinal ganglion cell death, irreversible optic nerve damage, and vision loss. The treatment of glaucoma consists of reducing intraocular pressure (IOP) to a target level that is presumed to prevent further optic nerve deterioration. This presumption of clinical stability should be reevaluated at each clinical encounter with the patient and a new lower target IOP level estimated if progression has occurred.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco: American Academy of Ophthalmology. <http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=a5a59e02-450b-4d50-8091-b2dd21ef1ff2>; 2005 Accessed 31.01.08.

  2. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95(4):601–604.

    CAS  PubMed  Google Scholar 

  3. Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol. 2002;47(Suppl 1):S2-S5.

    PubMed  Google Scholar 

  4. Lee PY, Podos SM, Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 1984;25(9):1087–1093.

    CAS  PubMed  Google Scholar 

  5. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131(1):19–24.

    CAS  PubMed  Google Scholar 

  6. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100(9):1297–1304.

    CAS  PubMed  Google Scholar 

  7. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2_ analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358.

    CAS  PubMed  Google Scholar 

  8. Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2_-1- isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989;96:1329–1337.

    CAS  PubMed  Google Scholar 

  9. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of Ocular Hypotensive Action of Bimatoprost (Lumigan) in Patients with Ocular Hypertension or Glaucoma. Ophthalmology. 2004;111:1658–1662.

    PubMed  Google Scholar 

  10. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol. 2003;135:688–703.

    CAS  PubMed  Google Scholar 

  11. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142.

    CAS  PubMed  Google Scholar 

  12. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(Suppl 1):S65-S76.

    PubMed  Google Scholar 

  13. Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63(3):333–338.

    CAS  PubMed  Google Scholar 

  14. Patel SC, Spaeth GL. Compliance in patients prescribed glaucoma medications. Ophthalmic Surg. 1995;26(3):233–236.

    CAS  PubMed  Google Scholar 

  15. Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. Arch Ophthalmol. 1994;112:1437–1445.

    CAS  PubMed  Google Scholar 

  16. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.

    PubMed  Google Scholar 

  17. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953.

    CAS  PubMed  Google Scholar 

  18. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006;22(5):971–976.

    CAS  PubMed  Google Scholar 

  19. Van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized trials. Ophthalmology. 2005;112:1177–1185.

    PubMed  Google Scholar 

  20. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110(3):609–614.

    PubMed  Google Scholar 

  21. Realini T, Fechtner RD. 56, 000 ways to treat glaucoma. Ophthalmology. 2002;109(11):1955–1956.

    PubMed  Google Scholar 

  22. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12(3):232–236.

    PubMed  Google Scholar 

  23. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111(9):1627–1635.

    PubMed  Google Scholar 

  24. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517.

    CAS  PubMed  Google Scholar 

  25. Katz LJ. Twelve-month evaluation of brimonidine-purite in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119–126.

    PubMed  Google Scholar 

  26. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10(3):220–226.

    CAS  PubMed  Google Scholar 

  27. Erdogan H, Toker I, Arici MK, et al. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. Jpn J Ophthalmol. 2003;47(5):473–478.

    CAS  PubMed  Google Scholar 

  28. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2007;24:302–309.

    CAS  PubMed  Google Scholar 

  29. Wilson RP, Kanal N, Spaeth GL. Timolol: its effectiveness in different types of glaucoma. Ophthalmology. 1979;86:43–50.

    CAS  PubMed  Google Scholar 

  30. Rettig ES, Larsson LI, Brubaker RF. The effect of topical timolol on epinephrine-stimulated aqueous humor flow in sleeping humans. Invest Ophthalmol Vis Sci. 1994;35:554–559.

    CAS  PubMed  Google Scholar 

  31. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389–395.

    CAS  PubMed  Google Scholar 

  32. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78(12):899–902.

    CAS  PubMed  Google Scholar 

  33. Stewart WC, Day DG, Sharpe ED, et al. Efficacy and safety of timolol solution once daily vs. timolol gel added to latanoprost. Am J Ophthalmol. 1999;128(6):692–696.

    CAS  PubMed  Google Scholar 

  34. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999;8(1):24–30.

    CAS  PubMed  Google Scholar 

  35. Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefe’s Arch Clin Exp Ophthalmol. 2004;242(9):767–770.

    Google Scholar 

  36. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs. monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120(7):915–922.

    CAS  PubMed  Google Scholar 

  37. Wang R-F, Serle JB, Podos SM, et al. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297–1299.

    CAS  PubMed  Google Scholar 

  38. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119-S129.

    PubMed  Google Scholar 

  39. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126(3):400–408.

    CAS  PubMed  Google Scholar 

  40. Arici MK, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22(1):37–42.

    Google Scholar 

  41. Chiselita D, Apatachioae I, Poiata I. The ocular hypotensive effect of the combination of latanoprost with dorzolamide. Oftalmologia. 1999;46(4):39–45.

    CAS  PubMed  Google Scholar 

  42. Franks W; Brinzolamide Study Group. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22(9):1643–1649.

    Google Scholar 

  43. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin. 2005;21(4):503–508.

    CAS  PubMed  Google Scholar 

  44. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma. 2007;16(4):352–357.

    PubMed  Google Scholar 

  45. O’Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133(6):836–837.

    PubMed  Google Scholar 

  46. Reis R, Queiroz CF, Santos LC, et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28(4):552–559.

    CAS  PubMed  Google Scholar 

  47. Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intrao­cular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112(4):603–608.

    PubMed  Google Scholar 

  48. Noecker RJ. Brimonidine purite 0.15% versus dorzolamide 2% used as adjunctive therapy to latanoprost. Presented at the annual meeting of the American Glaucoma Society, San Francisco, CA, 2007 (poster).

    Google Scholar 

  49. Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology. 2007;114(7):1248–1254.

    PubMed  Google Scholar 

  50. Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol. 2006;16(6):816–823.

    CAS  PubMed  Google Scholar 

  51. Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 2004;20(9):1333–1339.

    CAS  PubMed  Google Scholar 

  52. Netland PA, Michael M, Rosner SA, et al. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2003;20(1):20–30.

    CAS  PubMed  Google Scholar 

  53. Mundorf T, Dirks M, Noecker RJ, et al. Brimonidine purite 0.15% versus timolol 0.5% as adjunctive therapy with lipids. Presented at the annual meeting of the American Glaucoma Society, Snowbird, UT, 2005.

    Google Scholar 

  54. Nietgen GW, Schmidt J, Hesse L, et al. Muscarinic receptor functioning and distribution in the eye: molecular basis and implications for clinical diagnosis and therapy (review). Eye. 1999;13(Pt 3a):285–300.

    PubMed  Google Scholar 

  55. Toris CB, Zhan G-L, Zhao J, Camras CB, Yablonski ME. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131:722–728.

    CAS  PubMed  Google Scholar 

  56. Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111(5):662–665.

    CAS  PubMed  Google Scholar 

  57. Camras CB, Wang R-F, Podos SM. Effect of pilocarpine applied before or after prostaglandin F2a on IOP in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci. 1990;31:150.

    Google Scholar 

  58. Villumsen J, Alm A. Effect of the prostaglandin F2a analogue PhXA41 in eyes treated with pilocarpine and timolol. Invest Ophthalmol Vis Sci. 1992;33:1248.

    Google Scholar 

  59. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662–665.

    PubMed  Google Scholar 

  60. Kent AR, Vroman DT, Thomas TJ, Herbert RL, Crosson CE. Interaction of pilocarpine with latanoprost in patientswith glaucoma and ocular hypertension. J Glaucoma. 1999;8:257–262.

    CAS  PubMed  Google Scholar 

  61. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose and no pilocarpine therapy. Ophthalmology. 1999;106:386–390.

    CAS  PubMed  Google Scholar 

  62. Rulo AH, Greve EL, Hoyng PF. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology. 1997;104(9):1503–1507.

    CAS  PubMed  Google Scholar 

  63. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol. 1977;95:1378–1382.

    CAS  PubMed  Google Scholar 

  64. Wallace TR, Fraunfelder FT, Petursson GJ, Epstein DL. Decreased libido - a side effect of carbonic anhydrase inhibitor. Ann Ophthalmol. 1979;11:1563–1566.

    CAS  PubMed  Google Scholar 

  65. Epstein RJ, Allen RC, Lunde MW. Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. Ann Ophthalmol. 1987;19:48–50.

    CAS  PubMed  Google Scholar 

  66. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide: not a rare complication. Arch Intern Med. 1985;145:1815–1817.

    CAS  PubMed  Google Scholar 

  67. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology. 1981;88:261–265.

    CAS  PubMed  Google Scholar 

  68. Howlett SA. Renal failure associated with acetazolamide therapy for glaucoma. South Med J. 1975;68:504–506.

    CAS  PubMed  Google Scholar 

  69. Higenbottam T, Ogg CS, Saxton HM. Acute renal failure from the use of acetazolamide (Diamox). Postgrad Med J. 1978;54:127–128.

    CAS  PubMed  Google Scholar 

  70. Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol. 1985;100:79–81.

    CAS  PubMed  Google Scholar 

  71. Werblin TP, Pollack IP, Liss RA. Blood dyscrasias in patients using methazolamide (Neptazane) for glaucoma. Ophthalmology. 1980;87:350–354.

    CAS  PubMed  Google Scholar 

  72. Weiss IS. Hirsutism after chronic administration of acetazolamide. Am J Ophthalmol. 1974;78:327–328.

    CAS  PubMed  Google Scholar 

  73. Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol. 1997;115:550–553.

    CAS  PubMed  Google Scholar 

  74. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1999;106(12 Suppl):10–16.

    CAS  PubMed  Google Scholar 

  75. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121(4):453–457.

    CAS  PubMed  Google Scholar 

  76. Bastien N, Psaradellis F, Sampalis J, et al. Effect of dorzolamide-timolol (Cosopt(R)) co-administered with latanoprostTM or dorzolamide-timolol alone in patients with open angle glaucoma or ocular hypertension not adequately controlled on latanoprost. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006:441-B176.

    Google Scholar 

  77. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9):1230–1238.

    CAS  PubMed  Google Scholar 

  78. Nixon DR, Hollander DA. Comparison of the efficacy and tolerability of twice-daily CombiganTM vs. Cosopt(R) fixed-combination therapies. Presented at the annual meeting of the American Academy of Ophthalmology, New Orleans, LA, 2007.

    Google Scholar 

  79. Hommer A; Ganfort Investigators Group I. A double-masked, rando­mized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007; 17(1):53–62.

    CAS  PubMed  Google Scholar 

  80. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392–399.

    PubMed  Google Scholar 

  81. Neelakantan A, Vaishnav HD, Iyer SA, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13(2):130–136.

    PubMed  Google Scholar 

  82. Babizhayev MA, Brodskaya MW, Mamedov NG, et al. Clinical, structural and molecular phototherapy effects of laser irradiation on the trabecular meshwork of human glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 1990;228(1):90–100.

    CAS  PubMed  Google Scholar 

  83. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108(4):773–779.

    CAS  PubMed  Google Scholar 

  84. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial. Br J Ophthalmol. 2006;90(12):1490–1494.

    CAS  PubMed  Google Scholar 

  85. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999;83(6):718–722.

    CAS  PubMed  Google Scholar 

  86. Ruderman JM, Welch DB, Smith MF, et al. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol. 1987;104(3):218–224.

    CAS  PubMed  Google Scholar 

  87. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991;98(3):317–321.

    CAS  PubMed  Google Scholar 

  88. Hayreh SS. Anatomy and physiology of the optic nerve head. Trans Am Acad Ophthalmol Otolaryngol. 1974;78(2):OP240-OP254.

    CAS  PubMed  Google Scholar 

  89. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113(2):216–221.

    CAS  PubMed  Google Scholar 

  90. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107(7):1287.

    CAS  PubMed  Google Scholar 

  91. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119(12):1819–1826.

    CAS  PubMed  Google Scholar 

  92. Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol. 2001;119(1):89–95.

    CAS  PubMed  Google Scholar 

  93. Leske MC, Wu S-Y, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Ophthalmology. 2008;115:85–93.

    PubMed  Google Scholar 

  94. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917–2923.

    PubMed  Google Scholar 

  95. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41(9):2566–2573.

    CAS  PubMed  Google Scholar 

  96. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204–1212.

    CAS  PubMed  Google Scholar 

  97. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44(suppl 2):S141-S145.

    PubMed  Google Scholar 

  98. Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;suppl 2:S155-S162.

    Google Scholar 

Bibliography

  • Boger WP 3rd. Short-term “escape” and longterm “drift.” The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28(suppl):235–242.

    PubMed  Google Scholar 

  • Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832–833.

    CAS  PubMed  Google Scholar 

  • Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of anti­glaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol. 2008;92:729–734.

    CAS  PubMed  Google Scholar 

  • Lichter PR, Musch DC, Gillespie BW; the CIGTS Study Group Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953.

    CAS  PubMed  Google Scholar 

  • National Drug Code Data, July 2005. <http://www.fda.gov/cder/ndc/> Accessed 03.04.09.

  • Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13:130–136.

    PubMed  Google Scholar 

  • Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233–235.

    CAS  PubMed  Google Scholar 

  • Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–423.

    CAS  PubMed  Google Scholar 

  • Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–868.

    PubMed  Google Scholar 

  • Sherwood, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006; 124(9):1230–1238.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX, USA

    Jess T. Whitson MD

Authors
  1. Jess T. Whitson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2889 10th Avenue, N., Palm Springs, 33461, USA

    Paul N. Schacknow

  2. Casey Eye Institute, Dept. Ophthalmology, Oregon Health & Sciences University, SW. Terwilliger Blvd. 3375, Portland, 97201-4197, USA

    John R. Samples

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Whitson, J.T. (2010). Choosing Adjunctive Glaucoma Therapy. In: Schacknow, P., Samples, J. (eds) The Glaucoma Book. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76700-0_52

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-76700-0_52

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-76699-7

  • Online ISBN: 978-0-387-76700-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation